RELMADA THERAPEUTICS, INC. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Relmada completed a $160M equity offering (net ~$150M after fees), raising cash to $217.7M as of June 30, 2026, sufficient to fund operations through 2029 including Phase 3 NDV-01 RESCUE program. The company appointed Bipin Dalmia as Chief Business Officer and expects to file NDV-01 IND by year-end 2026, with Phase 3 initiation upon FDA clearance. Sepranolone IND filing also expected by year-end 2026. Share count increased to 106.7M shares outstanding; Q2 2026 net loss was $12.9M ($0.11/share); R&D expenses rose to $8.4M vs. $2.8M YoY.
Why this rating
Major capital raise ($160M net = 8.5x market cap) dramatically extends runway and de-risks development. Enables two Phase 3 programs. Material event for $18.9M company, though significant dilution and clinical/regulatory execution risk remain.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.